Dr. Janet Sim is the Vice President of Biologics Development. She has over 20 years of drug discovery research and development experience, which includes target validation, drug screening and identification, and drug manufacture for Phase I/II clinical development. At Tallac, she leads the effort for drug discovery and design as well as development of manufacturing processes for clinical drug supply. Prior to joining Tallac, Janet served as the Vice President of Protein Science at ALX Oncology and was a co-inventor of ALX148, a next generation CD47 blocker in development for multiple tumor indications. She was also involved in the development of manufacturing processes for ALX148 to support clinical studies. Prior to ALX Oncology, Janet held positions with increasing responsibilities at Chiron Corporation and Novartis. Janet received a Ph.D. in Molecular Biology from the National University of Singapore.